Abstract
Our investigator-initiated randomized trial in patients with chemorefractory metastatic colorectal cancer (mCRC) patients demonstrated improved PFS and OS in patients receiving bevacizumab combined with trifluridine/tipiracil (FTD/TPI) as compared with patients treated with FTD/TPI alone (Pfeiffer et al, Lancet Oncol 2020). In the present study, we have updated PFS and OS per February 1st, 2020. Furthermore, will evaluate markers for no benefit (1 month CT scan and increase in CEA), look for time to deterioration of performance status, and details regarding treatment-related hospitalization.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
